Stork Therapeutics is transforming how cell therapies are made and delivered. Our platform precisely delivers genetic cargo directly into a patient’s T cells, turning them into powerful CAR T cells inside the body to fight off cancer. Just as the stork has long symbolized the arrival of new life, we deliver genetic instructions that give patients a second chance. Our science builds on the work of Dr. Michel Sadelain (Columbia) a founder of the modern CAR T field, and Dr. Mike Mitchell (UPenn) whose breakthroughs in lipid nanoparticles advanced RNA medicines. Michel’s latest innovation is a next-generation cell therapy focused on curing AML that helps to mitigate toxicity while enhancing efficacy. Building on this foundation, Stork is reimagining how cell therapy can reach patients faster, more simply, and more accurately than ever before. Additional indications include triple-negative breast cancer (TNBC), a tough to treat indication.